vs
Side-by-side financial comparison of EPAM Systems (EPAM) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.4B, roughly 1.7× EPAM Systems). Zoetis runs the higher net margin — 25.3% vs 7.8%, a 17.5% gap on every dollar of revenue. On growth, EPAM Systems posted the faster year-over-year revenue change (12.8% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $268.1M). Over the past eight quarters, EPAM Systems's revenue compounded faster (9.9% CAGR vs 4.4%).
EPAM Systems, Inc. is an American company that specializes in software engineering services, digital platform engineering, and digital product design, operating out of Newtown, Pennsylvania. EPAM is a founding member of the MACH Alliance.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
EPAM vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $2.4B |
| Net Profit | $109.4M | $603.0M |
| Gross Margin | 30.1% | 70.2% |
| Operating Margin | 10.6% | 31.9% |
| Net Margin | 7.8% | 25.3% |
| Revenue YoY | 12.8% | 3.0% |
| Net Profit YoY | 5.9% | 3.8% |
| EPS (diluted) | $1.97 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4B | $2.4B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.4B | $2.5B | ||
| Q1 25 | $1.3B | $2.2B | ||
| Q4 24 | $1.2B | $2.3B | ||
| Q3 24 | $1.2B | $2.4B | ||
| Q2 24 | $1.1B | $2.4B | ||
| Q1 24 | $1.2B | $2.2B |
| Q4 25 | $109.4M | $603.0M | ||
| Q3 25 | $106.8M | $721.0M | ||
| Q2 25 | $88.0M | $718.0M | ||
| Q1 25 | $73.5M | $631.0M | ||
| Q4 24 | $103.3M | $581.0M | ||
| Q3 24 | $136.3M | $682.0M | ||
| Q2 24 | $98.6M | $624.0M | ||
| Q1 24 | $116.2M | $599.0M |
| Q4 25 | 30.1% | 70.2% | ||
| Q3 25 | 29.5% | 71.5% | ||
| Q2 25 | 28.8% | 73.6% | ||
| Q1 25 | 26.9% | 72.0% | ||
| Q4 24 | 30.4% | 69.5% | ||
| Q3 24 | 34.6% | 70.6% | ||
| Q2 24 | 29.3% | 71.7% | ||
| Q1 24 | 28.4% | 70.6% |
| Q4 25 | 10.6% | 31.9% | ||
| Q3 25 | 10.4% | 37.0% | ||
| Q2 25 | 9.3% | 36.7% | ||
| Q1 25 | 7.6% | 36.5% | ||
| Q4 24 | 10.9% | 31.6% | ||
| Q3 24 | 15.2% | 36.6% | ||
| Q2 24 | 10.5% | 33.0% | ||
| Q1 24 | 9.5% | 34.1% |
| Q4 25 | 7.8% | 25.3% | ||
| Q3 25 | 7.7% | 30.0% | ||
| Q2 25 | 6.5% | 29.2% | ||
| Q1 25 | 5.6% | 28.4% | ||
| Q4 24 | 8.3% | 25.1% | ||
| Q3 24 | 11.7% | 28.6% | ||
| Q2 24 | 8.6% | 26.4% | ||
| Q1 24 | 10.0% | 27.4% |
| Q4 25 | $1.97 | $1.37 | ||
| Q3 25 | $1.91 | $1.63 | ||
| Q2 25 | $1.56 | $1.61 | ||
| Q1 25 | $1.28 | $1.41 | ||
| Q4 24 | $1.80 | $1.29 | ||
| Q3 24 | $2.37 | $1.50 | ||
| Q2 24 | $1.70 | $1.37 | ||
| Q1 24 | $1.97 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.7B | $3.3B |
| Total Assets | $4.9B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.2B | $2.1B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $1.2B | $1.7B | ||
| Q4 24 | $1.3B | $2.0B | ||
| Q3 24 | $2.1B | $1.7B | ||
| Q2 24 | $1.8B | $1.6B | ||
| Q1 24 | $2.0B | $2.0B |
| Q4 25 | $3.7B | $3.3B | ||
| Q3 25 | $3.7B | $5.4B | ||
| Q2 25 | $3.7B | $5.0B | ||
| Q1 25 | $3.6B | $4.7B | ||
| Q4 24 | $3.6B | $4.8B | ||
| Q3 24 | $3.6B | $5.2B | ||
| Q2 24 | $3.4B | $5.0B | ||
| Q1 24 | $3.5B | $5.1B |
| Q4 25 | $4.9B | $15.5B | ||
| Q3 25 | $4.8B | $15.2B | ||
| Q2 25 | $4.7B | $14.5B | ||
| Q1 25 | $4.7B | $14.1B | ||
| Q4 24 | $4.8B | $14.2B | ||
| Q3 24 | $4.5B | $14.4B | ||
| Q2 24 | $4.2B | $14.2B | ||
| Q1 24 | $4.4B | $14.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $282.9M | $893.0M |
| Free Cash FlowOCF − Capex | $268.1M | $732.0M |
| FCF MarginFCF / Revenue | 19.0% | 30.7% |
| Capex IntensityCapex / Revenue | 1.1% | 6.7% |
| Cash ConversionOCF / Net Profit | 2.59× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $612.7M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.9M | $893.0M | ||
| Q3 25 | $294.7M | $938.0M | ||
| Q2 25 | $53.2M | $486.0M | ||
| Q1 25 | $24.2M | $587.0M | ||
| Q4 24 | $130.3M | $905.0M | ||
| Q3 24 | $242.0M | $951.0M | ||
| Q2 24 | $57.0M | $502.0M | ||
| Q1 24 | $129.9M | $595.0M |
| Q4 25 | $268.1M | $732.0M | ||
| Q3 25 | $286.4M | $805.0M | ||
| Q2 25 | $43.4M | $308.0M | ||
| Q1 25 | $14.8M | $438.0M | ||
| Q4 24 | $114.5M | $689.0M | ||
| Q3 24 | $237.0M | $784.0M | ||
| Q2 24 | $52.3M | $370.0M | ||
| Q1 24 | $123.2M | $455.0M |
| Q4 25 | 19.0% | 30.7% | ||
| Q3 25 | 20.5% | 33.5% | ||
| Q2 25 | 3.2% | 12.5% | ||
| Q1 25 | 1.1% | 19.7% | ||
| Q4 24 | 9.2% | 29.7% | ||
| Q3 24 | 20.3% | 32.8% | ||
| Q2 24 | 4.6% | 15.7% | ||
| Q1 24 | 10.6% | 20.8% |
| Q4 25 | 1.1% | 6.7% | ||
| Q3 25 | 0.6% | 5.5% | ||
| Q2 25 | 0.7% | 7.2% | ||
| Q1 25 | 0.7% | 6.7% | ||
| Q4 24 | 1.3% | 9.3% | ||
| Q3 24 | 0.4% | 7.0% | ||
| Q2 24 | 0.4% | 5.6% | ||
| Q1 24 | 0.6% | 6.4% |
| Q4 25 | 2.59× | 1.48× | ||
| Q3 25 | 2.76× | 1.30× | ||
| Q2 25 | 0.60× | 0.68× | ||
| Q1 25 | 0.33× | 0.93× | ||
| Q4 24 | 1.26× | 1.56× | ||
| Q3 24 | 1.77× | 1.39× | ||
| Q2 24 | 0.58× | 0.80× | ||
| Q1 24 | 1.12× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EPAM
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
